Daiichi Sankyo Healthcare To Launch H2 Blocker Liquid Digestive Drug
This article was originally published in PharmAsia News
Daiichi Sankyo Healthcare will launch Gaster 10 liquid digestive drug Oct. 16, the first H2-receptor antagonist liquid digestive drug in Japan, the company announced Oct. 9. The product is also combined with famotidine, an ingredient to constrain stomach acid. (Click here for more - Japanese language
You may also be interested in...
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.